Table 2.
Actionable Alteration and Inhibitor Recommendations
| Total N (%) | Cohort 1: Relapsed/Refractory N (%) | Cohort 2: Newly Diagnosed N (%) | |
|---|---|---|---|
| N | 153 | 101 | 52 |
| Actionable Alteration Identified [90% CI]* | 116 (76) [69-81] | 77 (77) [69-84] | 39 (74) [62-83] |
| Alteration Tier | |||
| 1 | 16 (14) | 9 (11) | 7 (18) |
| 2 | 6 (4) | 6 (8) | 0 (0) |
| 3 | 72 (62) | 46 (56) | 26 (68) |
| 4 | 7 (6) | 5 (6) | 2 (5) |
| 5 | 16 (14) | 13 (16) | 3 (8) |
| Additional Recommendation† | 3 (2) | 3 (3) | 0 (0) |
| Recommended Inhibitor Target [90% CI]** | 114 (75) [68-80] | 77 (76) [68-83] | 37 (71) [59-81] |
| MEK | 62 (41) | 39 (39) | 23 (44) |
| DOT1L/Menin | 23 (15) | 11 (11) | 12 (23) |
| FLT3 | 14 (9) | 9 (12) | 5 (9) |
| MTOR | 13 (8) | 9 (9) | 4 (8) |
| JAK1/2 | 14 (9) | 10 (10) | 4 (8) |
| JAK3 | 1 (1) | 1 (1) | 0 (0) |
| WEE1 | 6 (4) | 5 (5) | 1 (2) |
| HDAC | 5 (3) | 4 (4) | 1 (2) |
| ABL | 5 (3) | 5 (5) | 0 (0) |
| Gamma Secretase | 4 (3) | 2 (2) | 2 (4) |
| IDH1 | 4 (3) | 2 (2) | 2 (4) |
| CDK4/6 | 3 (2) | 2 (2) | 1 (2) |
| KIT | 3 (2) | 0 (0) | 3 (6) |
| PI3K | 3 (2) | 3 (3) | 0 (0) |
| TP53 | 2 (1) | 1 (1) | 1 (2) |
| AKT | 2 (1) | 2 (2) | 0 (0) |
| BCL2 | 2 (1) | 2 (2) | 0 (0) |
| BRAF | 2 (1) | 0 (0) | 2 (4) |
| CRM1 | 2 (1) | 1 (1) | 1 (2) |
| SRC | 2 (1) | 2 (2) | 0 (0) |
| PDGFRB | 1 (1) | 1 (1) | 0 (0) |
| CXCR4 | 1 (1) | 1 (1) | 0 (0) |
*
One patient had an actionable mutation found, but the patient died prior to having a treatment recommendation sent (case 100) and one patient had a BCR-ABL1 fusion identified but was already being treated with dasatinib so no additional recommendation was provided (case 90).
**
Patients may have had multiple recommended inhibitors.
†
Additional features of interest added retrospectively based on targetability during the course of the clinical trial (ex. TP53, CDKN2A)